Cell & Gene The Podcast Videocast

1. Regulatory Flexibility in CGT: Key Shifts and Implications with Monika Swietlicka 3/24/2026

   On episode 125 of Cell & Gene: The Podcast, Host Erin Harris talks to Halloran Consulting Group's Monika Swietlicka to discuss how the FDA is increasing flexibility in cell and gene therapy development without lowering evidentiary standards, emphasizing a risk-based, holistic approach.

2. Scaling CRISPR For Rare Disease With Aurora Therapeutics' Dr. Edward Kaye 3/10/2026

   On episode 124 of Cell & Gene: The Podcast, Aurora Therapeutics' CEO Dr. Edward Kaye discusses the company’s strategy for translating CRISPR gene editing into scalable, commercially viable medicines for rare diseases.

3. Simplifying Friction in Cell Therapy Clinical Trials with Dr. Panteli Theocharous 2/24/2026

   In episode 123 of Cell & Gene: The Podcast, Host Erin Harris talks to Dr. Panteli Theocharous, FIBMS, M.S., Ph.D., FRCPath, about the patient journey in cell therapy trials. 

4. Inside a Breakthrough HER2 Immunotherapy for PMO with OS Therapies' Paul Romness 2/10/2026

   In episode 122 of Cell & Gene: The Podcast, Host Erin Harris talks to Paul Romness, CEO of OS Therapies, to learn the company’s mission to address the severe unmet need in pulmonary metastatic osteosarcoma (PMO), a rare pediatric cancer with no established standard of care once it metastasizes.

5. Building Safer CRISPR Medicines for CVD with Scribe Therapeutics' Benjamin Oakes 1/28/2026

   In episode 121 of Cell & Gene: The Podcast, Host Erin Harris talks to Scribe Therapeutics' CEO and Co-Founder Benjamin Oakes about building next‑generation CRISPR and epigenetic editing tools to move genetic medicine beyond rare disease into common cardiometabolic indications.

6. Advancing Off-The-Shelf CRISPR CAR-T Therapies Into The Community Setting With Caribou Biosciences' Rachel Haurwitz 1/13/2026

   On episode 120 of Cell & Gene: The Podcast, Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company’s progress in developing CRISPR-edited, off-the-shelf CAR-T therapies for hematologic malignancies.

7. The Editors' Roundtable: A 2025 Retrospective of the Life Sciences Industry 1/8/2026

   We’re sharing this episode on Cell & Gene: The Podcast because Better Biopharma is a sister podcast within the Life Science Connect family. This conversation speaks directly to the challenges and opportunities our Cell & Gene: The Podcast audience is navigating right now.

8. Developing Itvisma for Broad-Range Treatment of SMA with Novartis' Dr. Norman Putzki 12/22/2025

   In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA).

9. Turning the Tumor Microenvironment Against Cancer with MGB's Alexander Cryer, Ph.D. 12/12/2025

   In Episode 118, Host Erin Harris talks to Alexander Cryer, Ph.D., Instructor in Medicine at Mass General Brigham, about a proof-of-concept strategy that reprograms tumor cells with mRNA lipid nanoparticles to overactivate the cGAS-STING pathway, forcing cancer cells to produce and export large amounts of the innate immune agonist cGAMP to stimulate surrounding immune cells and drive anti-tumor immunity.

10. Building Patient-Driven Culture and Leadership Resilience in CGT with Paul Perreault 12/2/2025

    On episode 117, Host Erin Harris welcomes Paul Perreault, Strategic Advisor, Board Member and former CEO of CSL, who shares insights from his decade leading the company through global expansion and the COVID-19 pandemic.